journal article·2014-04

Histological maturation of vascular smooth muscle cells in in situ tissue-engineered vasculature

Noriko Isayama, Goki Matsumura, Hideki Sato, Shojiro Matsuda, Kenji Yamazaki

Biomaterials· Volume 35· Issue 11
Publisher page

Abstract

The goal of regenerative medicine is to achieve histological and functional recovery to the level of the original tissue. For this purpose, we have developed a biodegradable scaffold to create cell-free in-situ tissue-engineered vasculature (iTEV) with good long-term results. However, the regeneration process of vascular smooth muscle cells (VSMCs) over time has yet to be examined. To evaluate the regeneration ability of VSMCs, the inferior vena cava of experimental animals was replaced with iTEV, and tested at 1, 3, 6, 12, and 24 months (n = 6 each) after implantation. Six animals were enrolled to compare 24-month iTEV and native vasculature in single individual samples. There were no complications throughout the study. Immunohistology, protein expression analysis, and biochemical findings indicate that iTEV can gradually regenerate and develop into a mature vessel within 24 months using our biodegradable scaffold. These results provide a time course for the regeneration of VSMCs within the tissue-engineered vascular autograft constructed using a biodegradable scaffold.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Cardiac and Coronary Surgery Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (14)

Show source-provided references
1. Long-term results of cell-free biodegradable scaffolds for in situ tissue-engineering vasculature: in a canine inferior vena cava model
2. Long-term results of cell-free biodegradable scaffolds for in situ tissue engineering of pulmonary artery in a canine model10.1016/j.biomaterials.2013.05.037 ↗
3. Evaluation of tissue-engineered vascular autografts10.1089/ten.2006.12.3075 ↗
4. Comparison of vascular smooth muscle cells in canine great vessels10.1186/1746-6148-9-54 ↗
5. Specific issues after extracardiac fontan operation: ventricular function, growth potential, arrhythmia, and thromboembolism10.1016/j.athoracsur.2005.02.024 ↗
6. Polytetrafluoroethylene graft calcification in patients with surgically repaired congenital heart disease: evaluation using multidetector-row computed tomography10.1016/j.ahj.2007.01.035 ↗
7. Kirklin · 1993
8. Optimal conduit size of the extracardiac Fontan operation based on energy loss and flow stagnation10.1016/j.athoracsur.2009.04.109 ↗
9. Cell-seeding techniques in vascular tissue engineering10.1089/ten.teb.2009.0527 ↗
10. Tissue-engineered blood vessels in pediatric cardiac surgery
11. The tissue-engineered vascular graft using bone marrow without culture10.1016/j.jtcvs.2004.10.030 ↗
12. First evidence that bone marrow cells contribute to the construction of tissue-engineered vascular autografts in vivo10.1161/01.CIR.0000092165.32213.61 ↗
13. A blood vessel model constructed from collagen and cultured vascular cells10.1126/science.2934816 ↗
14. Mulligan. Genetic interventions for vein bypass graft disease: a review10.1067/mva.2002.129112 ↗